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Background: Little is known about the relationship between acute exacerbations of COPD
(AECOPD) and gastroesophageal reflux disease (GERD). The aim of this study was to investigate
the effects on AECOPD of GERD diagnosed by a questionnaire.
Methods: The subjects were 221 consecutive patients with stable COPD who were evaluated
using the Frequency Scale for Symptoms of GERD (FSSG) and a prospective survey of AECOPD
for one year. Patients taking drugs for acid suppression were excluded. The association
between the frequency of AECOPD and the presence of GERD or FSSG score was examined.
Results: Based on the FSSG, the prevalence of GERD was 26.7%. AECOPD and hospitalization
due to AECOPD were significantly more frequent in patients with GERD than in those without
GERD, with crude relative risks of 3.42 and 3.66, respectively. Multivariate analyses showed
that GERD and COPD stage IV were significant predictors of hospitalization due to AECOPD,
independent of respiratory therapies or patient characteristics. The severity of GERD symp-
toms, as measured by the FSSG score, was significantly correlated with the frequencies of
AECOPD and hospitalization due to AECOPD. Similar correlations were seen for the FSSG sub-
scores for acid reflux and gastric dysmotility.
Conclusions: This prospective cohort study showed that GERD appears to be a predictive factor
for hospitalization due to AECOPD and that severer GERD symptoms may be associated with
more frequent AECOPD. Thus, further studies are warranted to evaluate the preventive effect
of the therapy for GERD on AECOPD.
ª 2011 Elsevier Ltd. All rights reserved.8 76 4131; fax: þ81 568 74 4516.
p.gr.jp (K. Takada).
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COPD is a common disease worldwide and the prevalence in
Japanese adults is estimated to be 10.9%.1 The main
purpose of management of COPD is to improve subjective
symptoms and exercise endurance capacity and to prevent
acute exacerbations of COPD (AECOPD),2 depending on the
severity of COPD. AECOPD causes temporal deterioration of
subjective symptoms and also induces a decline in lung
function, resulting in a poor prognosis.2,3
Gastroesophageal reflux disease (GERD) is also regarded
as amajor health burden, with a prevalence of 10e30% in the
Western population and 4.0e19.9% in Japanese adults.4
However, little is known about the relationship of AECOPD
and GERD, despite both being common diseases.5e9 This is
mainly due to the difficulty of diagnosis of GERD, since
definite diagnosis requires an endoscopic examination or 24 h
esophageal pH monitoring. In practice, it is difficult to
perform these procedures in a large number of patients in
screening, and this has led to development of many GERD
questionnaires for surrogate diagnosis.10 The Frequency
Scale for Symptoms of GERD (FSSG) was recently developed
and validated in the Japanese population.11 The FSSG has the
advantage of simplicity, since it includes only 12 items and is
easy to complete, even for elderly patients. Also, the sepa-
rate evaluation of symptoms caused by acid reflux or gastric
dysmotility in the FSSG allows quantification of subjective
symptoms of GERD and resultant objective evaluation of
therapeutic responses.11 Moreover, FSSG was reported to
reflect the severity of endoscopic findings of GERD.12
We previously performed screening of GERD in patients
with stable COPDusing the FSSGand reported the prevalence
of GERD and the relationship of GERD with AECOPD in the
previous year; patients with GERD, comparing to those
without GERD, had significantly more AECOPD, and the
presence of GERD was one of the significant risk factors
against AECOPD.13 We hypothesized that GERD may have
leading effect on AECOPD. To explore this association fur-
ther, we prospectively investigated the number of AECOPD
events and hospitalization due to AECOPD in the same cohort
and examined the effect of GERD on AECOPD.
Material and methods
The subjects were consecutive patients with stable COPD
who visited our hospital from July 2009 to November 2009.
The study was approved by the Institutional Review Board
of Komaki City Hospital, and all patients provided informed
consent. The diagnosis of COPD required symptoms of
chronic sputum or dyspnea on effort and FEV1/FVC <70%
after use of a bronchodilator.2 A stable condition was
defined as a period of more than one month without
exacerbation of COPD.
Patients were asked to complete the FSSG by themselves.
The results were assessed as the total FSSG score, acid reflux
score and gastric dysmotility score, and the total score
required for diagnosis of GERD was 8 points.11 Data were
collected for age, sex, smoking history, body mass index
(BMI), comorbidity, clinical COPD stage based on spirometric
parameters,2 and use of respiratory drugs. Comorbidities
were classified into malignant diseases, cardiovasculardiseases, other diseases, and none. Spirometry data were
collected within one year of the day of investigation.
Respiratory therapies included inhaled corticosteroids, long-
acting b-agonists, inhaled long-acting and short-acting
anticholinergics, theophylline, oral steroids, mucolytics,
and home oxygen therapy. Patients using histamine-2
receptor antagonists and proton pump inhibitors (PPIs) were
excluded because these drugs can affect GERD symptoms.
The numbers of episodes of AECOPD within the previous year
was also recorded. AECOPD was defined based on symptoms
of Anthonisen type 1 or 2 and prescription of additional
systemic corticosteroids or antibiotics.
The number of AECOPD episodes and hospitalization due
to AECOPD during the observational period of one year after
the day of investigation were evaluated prospectively.
Patient data are shown for groups with or without GERD.
Factors related to AECOPD were determined and the
correlation between FSSG score and the number of AECOPD
episodes was examined. An unpaired Student t-test,
ManneWhitney U test, chi-square test and KruskaleWallis
test were used to compare data between the groups as
appropriate. Significant factors in univariate analysis were
included in multivariate analysis using logistic regression,
which was performed to determine predictive factors. A
Spearman rank correlation test was used to test correla-
tions. Data are shown as the mean  standard deviation. A
p-value <0.05 was considered to be statistically significant.Results
A total of 221 patients with COPD were investigated in the
study. These patients had a mean age of 71.5 years old. A
comorbidity was present in 45%, including 40% with malig-
nant or cardiovascular diseases. The mean total FSSG score
was 4.7 points and the prevalence of GERDwas 26.7%. Of 181
patients for whom spirometry data were available, the pre-
dicted FEV1 was 67.7 27.3% and 62% were in clinical stage I
or II. The prevalence of GERD increased with progression of
COPD stage, but there was no significant relationship
between COPD stage and prevalence (p Z 0.250) or FSSG
score, namely severity of GERD (pZ 0.357) (Table 1). Simi-
larly no significant correlations between FSSG score and FEV1
(p Z 0.298) or %FEV1 (p Z 0.888) were identified. The
characteristics of the patients with and without GERD are
shown in Table 2. Only age differed significantly between
these two groups.
During the one-year observational period, the mean
number of AECOPDevents and the number of hospitalizations
due to AECOPDwere 0.75 1.00 and 0.28 0.64 for patients
with GERD, and 0.15 0.91 and 0.06 0.26 for thosewithout
GERD, respectively. Thus, GERD significantly increased the
frequency of AECOPD and hospitalization due to AECOPD,
with crude relative risks of 3.42 (95% confidence interval (CI),
2.06e5.69) and 3.66 (95% CI, 1.62e8.24), respectively.
The results of multivariate analysis using significant
factors in univariate analysis are presented in Tables 3 and 4.
Multivariate analysis revealed that the number of AECOPD
events in the previous year, BMI and COPD stage IV were
significant predictors for AECOPD; and that GERD and COPD
stage IV were predictors of hospitalization due to AECOPD,
independently of respiratory therapies or comorbidities.
Table 1 Number of patients and FSSG score by COPD stages.
COPD stage Number of patients With GERD (%) Without GERD Total FSSG scorea
I 56 11 (19) 45 4.62  4.66
II 60 13 (21) 47 3.66  3.60
III 35 11 (31) 24 5.48  6.59
IV 30 11 (36) 19 5.36  4.76
FSSG Z Frequency Scale for Symptoms of GERD.
a Data are shown as mean  SD.
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scores, reflecting the severity of GERD, and the number of
AECOPD events (r Z 0.461, p < 0.001) and the number of
hospitalizations due to AECOPD (r Z 0.459, p < 0.001).
Similar correlations of AECOPD events with acid reflux
scores and gastric dysmotility scores were also identified
(Table 5).Discussion
GERD occurs frequently in patients with bronchial asthma,14
interstitial lung diseases15 and respiratory symptoms,16 andTable 2 Patient characteristics and therapeutic interventions.
Total
Ageb 71.5  7.6
Sex (M/F) 210/11
Smoking (number)
Current smoker 38
Ex-smoker 180
Non-smoker 3
Comorbidity (number)
Cardiovascular 42
Malignant 36
None 121
Other 22
FSSG
Totalb 4.7  4.8
Acid refluxb 2.4  2.7
Gastric dysmotilityb 2.2  2.6
AECOPD events in previous yearb 0.34  0.73
Body mass indexb 21.68  3.45
Inhaled corticosteroidsa 166/55
Long-acting beta-agonistsa 137/84
Long-acting anticholinergicsa 73/148
Short-acting anticholinergicsa 208/13
Theophyllinea 174/47
Oral steroidsa 217/4
Mucolyticsa 172/49
Home oxygen therapya 194/27
AECOPD Z acute exacerbations of COPD.
a Number of patients with no use/use.
b Data are shown as mean  SD.affects the clinical courses of these diseases. Therefore,
GERD is a morbidity that is strongly related to respiratory
disorders. In this prospective study, the prevalence of GERD
defined by the FSSG was 26.7% in stable COPD patients and
the relationship between AECOPD and the presence and
severity of GERD appeared to be significant and independent
of respiratory therapies and comorbidities. The relative risks
of AECOPD and hospitalization due to AECOPD were 3.4 and
3.6, respectively. Moreover, the frequency of AECOPD was
significantly related to the severity of GERD symptoms. This
relationship has been reported previously, but as far as we
are aware, it has not been examined in a prospective study
with inclusion of data for respiratory therapies.With GERD Without GERD p-value
68.8  7.2 72.5  7.6 0.001
57/2 153/9 0.512
0.315
13 25
46 134
0 3
0.349
7 35
12 24
33 88
7 15
11.1  4.4 2.3  2.0 <0.001
5.7  3.0 1.1  1.2 <0.001
5.3  2.8 1.7  1.3 <0.001
0.49  0.85 0.29  0.67 0.118
20.96  3.54 21.93  3.39 0.109
43/16 123/39 0.643
41/18 96/66 0.165
16/43 57/105 0.259
55/4 153/9 0.732
45/14 129/33 0.589
57/2 160/2 0.287
43/16 129/33 0.285
49/10 145/17 0.194
Table 3 Significant factors associated with AECOPD.
Univariate analysis Multivariate analysis
p-value OR 95% CI p-value OR 95% CI
GERD <0.001 5.905 2.690e12.963
Number of AECOPD events in previous year <0.001 5.894 2.709e12.822 <0.001 12.599 3.131e50.706
Body mass index <0.001 0.632e0.804 <0.001 0.726 0.577e0.914
COPD stage I 1.000 1.000
Stage II 0.298 3.265 0.350e30.396 0.347 3.117 0.291e33.413
Stage III 0.008 17.778 2.066e152.957 0.209 4.702 0.419e52.760
Stage IV <0.001 37.333 4.508e309.158 0.005 109.704 3.883e3099.135
Oral steroids 0.031 12.343 1.246e122.293
Home oxygen therapy 0.001 4.319 1.794e10.396
OR Z odds ratio, CI Z confidence interval, AECOPD Z acute exacerbations of COPD.
1534 K. Takada et al.In patients with COPD, the reported prevalence of GERD
is 17e62%.5,6,8,17e19 In our population, the prevalence of
GERD was 26.7%, which is a higher frequency than that
found in the general Japanese population, consistent with
the findings of Terada et al.5 Concerning the relationship
between GERD and lung function, a greater decline in FEV1
has been related to more symptoms of GERD,7,20 while
other studies have found no relationship.6,19 In our study,
there was no significant relationship between lung function
and the prevalence or severity of GERD, which suggests that
GERD may be a more common comorbidity in patients with
COPD than in the general population, independently of the
severity of COPD.
Despite some reports showing the relevance of GERD to
AECOPD, only a few studies have investigated this relation-
ship prospectively5,7,9 or with inclusion of COPD therapies.8
Our study revealed that BMI, COPD stage IV and the number
of AECOPD events in the previous year were predictive
factors for AECOPD, and that GERD and COPD stage IV were
predictive factors for hospitalization due to AECOPD,Table 4 Significant predictors of hospitalization due to AECOPD
Univariate analysis
p-value OR 9
GERD 0.001 4.340
Number of AECOPD events in
previous year
0.006 3.636
Body mass index 0.005 0.772
COPD stage I 1.000
Stage II 0.960 0.932
Stage III 0.047 9.167
Stage IV 0.002 27.500 3
Oral steroids 0.022 10.421
Home oxygen therapy <0.001 7.583
OR Z odds ratio, CI Z confidence interval, AECOPD Z acute exacerindependently of COPD therapies and comorbidities. GERD
may lead to more severe AECOPD, including that requiring
hospitalization. A recent multicenter study also found that
a history of AECOPD in the previous year, GERD symptoms,
poor quality of life and elevated white blood cell count were
predictors of AECOPD.9 Furthermore, we found a significant
correlation between FSSG scores and the numbers of AECOPD
events and hospitalizations due to AECOPD. These results
indicate that greater severity of GERD symptomsmay lead to
more frequent AECOPD, consistent with other investiga-
tions.5,8,21 In addition, FSSG subscores showed similar asso-
ciations to those of the total score, which may suggest that
GERD in COPD patients is caused by both acid reflux and
gastric dysmotility.
This study has several limitations. First, it is unclear
whether the FSSG is appropriate for diagnosis of GERD. A
total FSSG score 8 points has a sensitivity, specificity and
agreement with endoscopic diagnosis of 62%, 59% and 60%,
respectively.11 The FSSG is thought to be valid for screening
surveillance of GERD, with equal diagnostic value4,12 to the.
Multivariate analysis
5% CI p-value OR 95% CI
1.723e10.936 0.034 4.091 1.107e15.119
1.444e9.160
0.644e0.925
1.000
0.057e15.273 0.953 0.918 0.050e16.912
1.023e82.139 0.186 5.159 0.452e58.923
.306e228.781 0.047 29.115 1.046e810.646
1.388e78.235
2.816e20.425
bations of COPD.
Table 5 Relationships of FSSG score with the number of AECOPD events and hospitalization due to AECOPD.
Total score Acid reflux Gastric dysmotility
Number of AECOPD events r 0.461 0.460 0.471
p-value <0.001 <0.001 <0.001
Hospitalization due to AECOPD r 0.459 0.447 0.486
p-value <0.001 <0.001 <0.001
r Z correlation coefficient, AECOPD Z acute exacerbations of COPD.
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(QUEST).22 However, this refers to the general population,
and the specific effect of COPD itself on the FSSG score
requires validation. Moreover, because asymptomatic GERD
is reported to be frequent in patients with COPD,19 further
studies are also needed to clarify whether the FSSG has the
same sensitivity for detection of GERD in patients with
COPD as that in the general population.
Secondly, the frequency of AECOPD in our study pop-
ulation was lower than that in other studies and respiratory
medicines did not protect against AECOPD. These findings
may be caused by the relatively mild COPD in the pop-
ulation, since two-thirds of the patients were stage I or II,
the small sample size and the strict definition of AECOPD as
a condition that required therapeutic intervention. Actu-
ally, Hurst et al. found a similar frequency of AECOPD and
hospitalization in patients with COPD stages IIeIV, using
a definition of AECOPD that was similar to our definition.9
Thus, the effect of GERD in promoting AECOPD may be
stronger than the protective effect of respiratory drugs.
Anyway, this study is thought to be underpower to show
the conclusive relationship between GERD and AECOPD,
due to small sample size or methodological weak points, so
well-conducted larger studies are needed to establish this
relationship.
Prevention of AECOPD requires detection and treatment
of GERD. PPIs are the standard drugs for GERD,4 and
interventions using PPIs in COPD cases have been shown to
improve respiratory symptoms and decrease AECOPD.23,24
This warrants further prospective studies. However, such
studies need to be performed in very large patient pop-
ulations, as for bronchial asthma,25 and this requires
a simple screening method for GERD. The FSSG can be
completed quickly and easily, even by elderly patients, and
interpretation of the scores is simple, in contrast to other
questionnaires. Moreover, the FSSG can be used for evalu-
ation of the treatment effect.11 Terada et al. showed that
the FSSG has the same sensitivity as QUEST in COPD
patients,5 and the FSSG is likely to have clinical value in
detection of GERD in COPD patients. We also note that
potential adverse effects of PPIs are of concern in treat-
ment of GERD, such as pneumonia,26 osteoporosis and
nutritional disorders.27
In conclusion, the results of this study showed that GERD
appear to be a major comorbidity that is associated with
hospitalization due to AECOPD, independent of COPD sev-
erity or respiratory therapies. Patients with more symptoms
of GERD may be more likely to develop AECOPD. Thus,
detection of GERD using a practical approach such as the
FSSG is important for early therapeutic intervention that
may result in prevention of AECOPD.Authorship
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